<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MASH: The Silent Liver Epidemic | Adi Desai</title>
    <meta name="description" content="Understanding metabolic dysfunction-associated steatohepatitis, the liver disease affecting a quarter of the world's population.">
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>A</text></svg>">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Sora:wght@300;400;500;600&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="post.css">
</head>
<body id="top">
    <div class="noise"></div>

    <nav class="nav">
        <a href="index.html" class="nav-back">Blog</a>
        <a href="https://adidesai.org" class="logo">A</a>
        <div class="nav-right">
            <a href="../index.html">Home</a>
            <a href="index.html">Blog</a>
            <a href="../index.html#contact" class="nav-cta">Contact</a>
        </div>
    </nav>

    <header class="article-header">
        <div class="article-header-content">
            <a href="index.html" class="back-link">← Back to Blog</a>
            <div class="article-meta">
                <span class="article-date">January 4, 2025</span>
                <span class="article-reading">8 min read</span>
            </div>
            <h1 class="article-title">MASH: The Silent Liver Epidemic</h1>
            <p class="article-subtitle">Formerly known as NASH, metabolic dysfunction-associated steatohepatitis is becoming the leading cause of liver transplants—and most people have never heard of it.</p>
            <div class="article-tags">
                <span class="article-tag">Metabolic</span>
            </div>
        </div>
    </header>

    <section class="key-stats">
        <div class="key-stats-content">
            <div class="key-stat">
                <div class="key-stat-value">25%</div>
                <div class="key-stat-label">Global population with fatty liver</div>
            </div>
            <div class="key-stat">
                <div class="key-stat-value">5%</div>
                <div class="key-stat-label">Progress to MASH</div>
            </div>
            <div class="key-stat">
                <div class="key-stat-value">#1</div>
                <div class="key-stat-label">Growing cause of liver transplant</div>
            </div>
            <div class="key-stat">
                <div class="key-stat-value">2024</div>
                <div class="key-stat-label">First drug approved</div>
            </div>
        </div>
    </section>

    <main class="article-content">
        <article class="article-body">
            <h2>What is MASH?</h2>
            <p><strong>MASH</strong> (metabolic dysfunction-associated steatohepatitis) is a progressive liver disease characterized by fat accumulation, inflammation, and liver cell damage—in people who drink little to no alcohol. It was previously called <strong>NASH</strong> (non-alcoholic steatohepatitis), but the name was changed in 2023 to better reflect its metabolic origins and reduce stigma.<a href="#ref1" class="cite">[1]</a></p>

            <p>MASH exists on a spectrum:</p>

            <div class="info-box">
                <div class="info-box-title">The Spectrum of Fatty Liver Disease</div>
                <ul>
                    <li><strong>MASLD (formerly NAFLD):</strong> Fat in the liver without significant inflammation</li>
                    <li><strong>MASH (formerly NASH):</strong> Fat + inflammation + liver cell damage (ballooning)</li>
                    <li><strong>MASH with fibrosis:</strong> Scarring begins to develop</li>
                    <li><strong>Cirrhosis:</strong> Extensive scarring; liver function compromised</li>
                    <li><strong>Liver cancer:</strong> Increased risk with cirrhosis</li>
                </ul>
            </div>

            <h2>The Silent Epidemic</h2>
            <p>MASH is called "silent" because it typically causes <strong>no symptoms</strong> until advanced stages. Most people are diagnosed incidentally—abnormal liver tests on routine bloodwork, or fatty liver seen on imaging for something else.</p>

            <p>The numbers are staggering:</p>
            <ul>
                <li><strong>1 in 4 adults</strong> worldwide has fatty liver disease (MASLD)<a href="#ref2" class="cite">[2]</a></li>
                <li>About <strong>20-30%</strong> of those with MASLD have MASH</li>
                <li>MASH is the <strong>fastest-growing</strong> indication for liver transplant</li>
                <li>By 2030, MASH is projected to become the <strong>#1 cause</strong> of liver transplant in the US</li>
            </ul>

            <p>This tracks perfectly with the obesity and diabetes epidemics. MASH shares the same metabolic roots: <strong>insulin resistance, obesity, and metabolic syndrome</strong>.</p>

            <h2>How MASH Damages the Liver</h2>
            <p>The liver normally stores small amounts of fat. In MASLD/MASH, excess calories—particularly from sugar and refined carbohydrates—overwhelm the liver's capacity. The fat triggers:</p>

            <ol>
                <li><strong>Oxidative stress:</strong> Toxic reactive oxygen species damage liver cells</li>
                <li><strong>Inflammation:</strong> Immune cells infiltrate, trying to repair damage</li>
                <li><strong>Cell death:</strong> Hepatocytes balloon and die (ballooning degeneration)</li>
                <li><strong>Fibrosis:</strong> Repeated injury activates stellate cells, which produce scar tissue</li>
            </ol>

            <p>Over years or decades, accumulated scar tissue can progress to <strong>cirrhosis</strong>—irreversible scarring that impairs liver function. Cirrhosis also dramatically increases the risk of <strong>hepatocellular carcinoma</strong> (liver cancer).<a href="#ref5" class="cite">[5]</a></p>

            <h2>Risk Factors</h2>
            <div class="info-box">
                <div class="info-box-title">Who is at Risk?</div>
                <ul>
                    <li><strong>Obesity:</strong> Present in 80-90% of MASH patients</li>
                    <li><strong>Type 2 diabetes:</strong> 60-70% of diabetics have fatty liver</li>
                    <li><strong>Metabolic syndrome:</strong> High blood pressure, high triglycerides, low HDL</li>
                    <li><strong>Genetics:</strong> PNPLA3 gene variant increases risk 3-5 fold</li>
                    <li><strong>Ethnicity:</strong> Higher prevalence in Hispanic populations</li>
                </ul>
            </div>

            <h2>Diagnosis</h2>
            <p>Diagnosing MASH is challenging because:</p>
            <ul>
                <li><strong>Blood tests</strong> (ALT, AST) can be normal even with significant disease</li>
                <li><strong>Ultrasound</strong> can detect fat but not inflammation or fibrosis</li>
                <li><strong>Liver biopsy</strong> remains the gold standard but is invasive</li>
            </ul>

            <p>Newer non-invasive tools are improving diagnosis:</p>
            <ul>
                <li><strong>FibroScan:</strong> Uses ultrasound elastography to measure liver stiffness (fibrosis)</li>
                <li><strong>MRI-PDFF:</strong> Precisely quantifies liver fat</li>
                <li><strong>Blood biomarkers:</strong> FIB-4, ELF test, and others estimate fibrosis stage</li>
            </ul>

            <h2>Treatment: Finally, a Breakthrough</h2>
            <p>For years, the only treatments were <strong>lifestyle modification</strong>—weight loss through diet and exercise. Losing 7-10% of body weight can resolve MASH in many patients. But sustaining weight loss is notoriously difficult.</p>

            <p>In March 2024, the FDA approved <strong>resmetirom (Rezdiffra)</strong>—the first drug specifically approved for MASH with moderate to advanced fibrosis.<a href="#ref3" class="cite">[3]</a> It's a thyroid hormone receptor agonist that:</p>
            <ul>
                <li>Increases liver fat metabolism</li>
                <li>Reduces inflammation</li>
                <li>May slow or reverse fibrosis</li>
            </ul>

            <p>GLP-1 agonists like semaglutide (Ozempic/Wegovy) also show significant promise. By causing weight loss and improving metabolic parameters, they can resolve MASH in many patients—though they're not yet FDA-approved for this indication specifically.</p>

            <h2>Prevention</h2>
            <p>MASH is largely <strong>preventable</strong> through the same strategies that prevent obesity and diabetes:</p>
            <ul>
                <li>Maintain healthy weight</li>
                <li>Limit added sugars and refined carbohydrates</li>
                <li>Regular physical activity</li>
                <li>Avoid excessive alcohol (even "moderate" drinking may worsen fatty liver)</li>
                <li>Control diabetes and metabolic syndrome</li>
            </ul>

            <blockquote>
                <p>"The liver is remarkably resilient. If caught early, fatty liver disease is completely reversible. The key is awareness and action before cirrhosis develops."</p>
            </blockquote>

            <div class="sources">
                <h2>Sources</h2>
                <ol>
                    <li id="ref1">Rinella, M. E., et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966-1986.</li>
                    <li id="ref2">Younossi, Z. M., et al. (2023). The global epidemiology of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology, 20, 571-589.</li>
                    <li id="ref3">Harrison, S. A., et al. (2024). Resmetirom for NASH with liver fibrosis. NEJM, 390(6), 497-509.</li>
                    <li id="ref4">American Liver Foundation. (2024). NASH/MASH. <a href="https://liverfoundation.org" target="_blank">liverfoundation.org</a></li>
                    <li id="ref5">Loomba, R., et al. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 184(10), 2537-2564.</li>
                </ol>
            </div>
        </article>
    </main>

    <a href="#top" class="back-to-top" title="Back to top">↑</a>

    <footer class="footer">
        <span>Adi Desai 2025</span>
        <span>All opinions are my own</span>
    </footer>
</body>
</html>
